According to a recent LinkedIn post from Hemanext, the company is promoting hypoxic storage technology designed to preserve red blood cell quality over longer storage periods. The post cites published research suggesting that hypoxically stored red blood cells may function more like freshly donated cells at the time of transfusion, and targets clinicians and hospitals as key decision makers.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post highlights potential clinical advantages for chronic transfusion patients, where clinicians often prefer younger blood units due to natural degradation over time. For investors, this emphasis points to Hemanext’s focus on positioning its Hemanext ONE platform in the transfusion medicine value chain, with revenue potential tied to hospital adoption and integration into blood supply and storage workflows.
By directing readers to contact the company to access hypoxic red blood cells, the post suggests an active commercial push rather than a purely R&D stage initiative. If hospitals and blood centers validate both clinical benefits and cost-effectiveness, broader uptake could strengthen Hemanext’s competitive position in blood technology, support recurring revenue from disposables or equipment, and enhance its attractiveness as a partner for larger medtech or blood service organizations.